Chemical Namepegvaliase-pqpz
Dosage FormInjectable (subcutaneous; 2.5 mg/0.5 mL, 10 mg/0.5 mL, 20 mg/mL)
Drug ClassEnzymes
CompanyBioMarin Pharmaceutical Inc.
Approval Year2018


  • Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.
Last updated on 12/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Palynziq (pegvaliase-pqpz) Prescribing Information2018Biomarin Pharm